Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pGx9501
- Development stage
- Unknown
- Lead developer
- Advaccine Biotechnology
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
pGx9501 is a DNA vaccine candidate developed by Advaccine Biopharmaceuticals in collaboration with the Sichuan Provincial Center for Disease Control and Prevention for the prevention of COVID-19. The vaccine utilizes a plasmid DNA vector to deliver the genetic sequence of the SARS-CoV-2 spike protein into host cells, where the protein is expressed to elicit both neutralizing antibodies and T-cell mediated immune responses. It has been investigated in Phase I and II clinical trials, including studies evaluating its safety and immunogenicity as a heterologous booster dose in individuals previously immunized with inactivated SARS-CoV-2 vaccines.
02
Targets
MHC-I/II-S (Major Histocompatibility Complex class I and II molecules presenting SARS-CoV-2 spike-derived peptides)TCR-spike-pMHC (T-cell receptor recognizing SARS-CoV-2 spike peptide–MHC complex)ACE2 (Angiotensin-converting enzyme 2)Severe acute respiratory syndrome coronavirus 2 spike glycoprotein (SARS-CoV-2 spike protein)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on pGx9501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pGx9501.